Literature DB >> 17994379

Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran.

Mehrnoosh Kosaryan1, Koorosh Vahidshahi, Hosein Karami, Morteza Alizadeh Forootan, Mehdi Ahangari.   

Abstract

Beta-thalassemia major (TM) is the most prevalent genetic disease in Mazandaran Province. Currently, about 2,700 TM patients have been registered and are under treatment in the province. This study was undertaken to evaluate the survival of patients attending a dedicated clinic at the Boo Ali Sina Teaching Hospital, Sari, Iran, which was established in 1986. This survival analysis was conducted from July 2004 to September 2006. New deaths were updated in September 2006. A total of 1,010 medical records were reviewed. Place of residence, date of birth, first transfusion, initiation date of chelation, diagnosis of cardiac complications, diabetes and death were recorded. Compliance to treatment assessed by calculating the percentage of actual usage to prescribed iron chelator medicine and also by asking the attending nurse who was constantly present throughout the last 15 years. Validity of the opinion of the nurse was ascertained in a previous study. Kaplan-Meier statistics were used for analysis. The odds ratio (OR) and its 95% confidence interval (CI) for some risk factors of death were calculated. The survival rate of patients born before and after 1986 was also compared. Survival of both genders for birth cohort before and after 1986 was not statistically significant although the cohort of patients born after 1986 was better at 30 years old (68 vs. 80%). The survival of TM patients is improving but the prevalence of complications is high.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994379     DOI: 10.1080/03630260701641294

Source DB:  PubMed          Journal:  Hemoglobin        ISSN: 0363-0269            Impact factor:   0.849


  9 in total

1.  A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

Authors:  Pattara Leelahavarong; Usa Chaikledkaew; Suradej Hongeng; Vijj Kasemsup; Yoel Lubell; Yot Teerawattananon
Journal:  BMC Health Serv Res       Date:  2010-07-16       Impact factor: 2.655

2.  Survival analysis of thalassemia major patients using Cox, Gompertz proportional hazard and Weibull accelerated failure time models.

Authors:  Enayatollah Bakhshi; Reza Ali Akbari Khoei; Azita Azarkeivan; Maryam Kooshesh; Akbar Biglarian
Journal:  Med J Islam Repub Iran       Date:  2017-12-17

3.  Cinchona alkaloids as natural fetal hemoglobin inducing agents in human erythroleukemia cells.

Authors:  Fizza Iftikhar; Hamad Ali; Syed Ghulam Musharraf
Journal:  RSC Adv       Date:  2019-06-04       Impact factor: 4.036

4.  Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of iran.

Authors:  Elham Ahmadnezhad; Nariman Sepehrvand; Farshid Fayyaz Jahani; Sanaz Hatami; Catauon Kargar; Majid Mirmohammadkhani; Shahrzad Bazargan-Hejazi
Journal:  Int J Prev Med       Date:  2012-10

5.  Influence of splenectomy on immunoglobulins and complement components in major thalassemia.

Authors:  Ali Asghar Darzi; Sakineh Kamali; Mohammad Khakzad
Journal:  Caspian J Intern Med       Date:  2015

6.  Analysis of survival data in thalassemia patients in Shiraz, Iran.

Authors:  Abdolreza Rajaeefard; Mahmoud Hajipour; Hamid Reza Tabatabaee; Jafar Hassanzadeh; Shahab Rezaeian; Zahra Moradi; Mehdi Sharafi; Mohsen Shafiee; Ali Semati; Sanaz Safaei; Maryam Soltani
Journal:  Epidemiol Health       Date:  2015-07-07

Review 7.  Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015.

Authors:  Hadi Darvishi Khezri; Ebrahim Salehifar; Mehrnoush Kosaryan; Aily Aliasgharian; Hossein Jalali; Arash Hadian Amree
Journal:  Adv Pharmacol Sci       Date:  2016-02-21

8.  The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran.

Authors:  Alireza Ansari-Moghaddam; Hossein Ali Adineh; Iraj Zareban; Mehdi Mohammadi; Mahtab Maghsoodlu
Journal:  Epidemiol Health       Date:  2018-10-03

9.  Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System.

Authors:  Mehrnoush Kosaryan; Hossein Karami; Hadi Darvishi-Khezri; Rosetta Akbarzadeh; Aily Aliasgharian; Khadijeh Bromand
Journal:  Iran J Public Health       Date:  2019-07       Impact factor: 1.429

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.